Clinical trials: Intravenous
Healthy Volunteers
The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking
This will be a phase 1 randomized, double-blind, 2-period, 2-sequence crossover trial enrolling 6 healthy volunteers to assess the impact of IV-administered Bendavia on the endothelial dysfunction induced by a single cigarette.
- Trial name
- NCT01518985
- Testing
- Bendavia, Sterile saline (0.9%), Cigarette smoking
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Mighty Therapeutics, Inc.
Refractory, Multiple Myeloma
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
The purpose of this study is to assess the safety/tolerability and determine the Japanese recommended dose (RD) of bortezomib administered as a once-daily intravenous bolus twice weekly for 2 consecutive weeks(Days 1, 4, 8, and…
- Conditions
- Refractory, Multiple Myeloma, Relapse
- Trial name
- NCT00752518
- Testing
- bortezomib
- Volunteers
- 35 people
- Sponsor
- Janssen Pharmaceutical K.K.
Leukemia, Myeloid, Acute
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
This is a Phase 1, open label, two-part study to determine recommended phase 2 dose (RP2D) and schedule of GSK3745417 administration in participants with relapsed/refractory AML or HR-MDS.
- Trial name
- NCT05424380
- Testing
- GSK3745417
- Where
- 10 sites in Canada, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis, Gastrointestinal Disease
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis.
- Conditions
- Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease
- Trial name
- NCT00073047
- Testing
- Daclizumab
- Where
- 35 sites in United States, Belgium and 1 more
- Volunteers
- 150 people
- Sponsor
- Facet Biotech
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550…
- Trial name
- NCT00551174
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 781 people
- Sponsor
- Hoffmann-La Roche
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia.
- Conditions
- Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
- Trial name
- NCT06255782
- Testing
- ECUR-506
- Where
- 12 sites in United States, Australia and 2 more
- Volunteers
- 20 people
- Sponsor
- iECURE, Inc.
Gout
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous doses of Puricase, administered intravenously, in 40 patients with symptomatic gout.
- Trial name
- NCT00080210
- Testing
- Puricase
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Savient Pharmaceuticals
Bacterial Infections.
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A phase one study to characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
- Trial name
- NCT01946568
- Testing
- Dalbavancin
- Where
- 12 sites in United States, Estonia
- Volunteers
- 36 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Skin Infections
Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection
The purpose of this study is to evaluate the potential effect and safety of two different doses of PZ-601 and to compare this with another antibiotic that is approved by the US Food and Drug Administration (also known as FDA) to…
- Trial name
- NCT00671580
- Testing
- PZ-601, Standard of Care
- Where
- 15 sites in United States
- Volunteers
- 99 people
- Sponsor
- Protez Pharmaceuticals, Inc.
Carcinoma Surgery, Parenteral Nutrition
The Impact of Omega-3 Fat Emulsion on Clinical Outcome of Post-Operative Cancer Patients
The purpose of this study is to evaluate clinical safety and effect of Omega-3 fat oil emulsion on outcome in post-operative cancer patients.
- Conditions
- Carcinoma Surgery, Parenteral Nutrition, Post-Operative Hospital Stay
- Trial name
- NCT00292279
- Testing
- Omega-3 fish oil emulsion (Omegaven ), long-chain triglyceride
- Where
- 5 sites in China
- Volunteers
- 206 people
- Sponsor
- Sino-Swed Pharmaceutical Corporation
Healthy
A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants
The purpose of this study is to find out if different doses of CNTO 3157 are well tolerated in both Japanese and Caucasian men as well as to understand how the body absorbs and removes the study drug after being injected or…
- Trial name
- NCT02008279
- Testing
- 100 mg CNTO 3157, 300 mg CNTO 3157, 600 mg CNTO 3157
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Evaluate the Use of a Graded Infusion of Intravenous Glucose in the Assessment of Insulin Secretion Rates (MK-0000-078)
A two period pilot study to determine if a graded glucose infusion using a glucose (20% dextrose [D20]) intravenous infusion can be properly implemented and will be well tolerated in healthy subjects.
- Trial name
- NCT01021462
- Testing
- Comparator: graded infusion of intravenous glucose
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics of BI 765423 in healthy male subjects.
- Trial name
- NCT06232252
- Testing
- BI 765423
- Where
- Belgium
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT02624778
- Testing
- LY3002813
- Where
- 9 sites in United States, Japan
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Solid Tumor Cancer
SB-743921 In Patients With Solid Tumors
The purpose of this study is to find a dose of SB-743921 in adult patients with solid tumors or lymphoma who have progressed on standard therapy or who have relapsed.
- Trial name
- NCT00136513
- Testing
- SB-743921
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Medical Oncology
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral BAY1217389 given in combination with intravenous (IV) paclitaxel using an intermittent dosing schedule (2 days on / 5…
- Trial name
- NCT02366949
- Testing
- BAY1217389, Paclitaxel
- Where
- 7 sites in United States, Netherlands
- Volunteers
- 75 people
- Sponsor
- Bayer
Pulmonary Fibrosis Secondary to Systemic Sclerosis
QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
This study will evaluate the safety, tolerability, and mechanism of action of multiple doses of QAX576 in patients with pulmonary fibrosis secondary to systemic sclerosis
- Trial name
- NCT00581997
- Testing
- QAX576
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Premature Ovarian Insufficiency
Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI
A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI).
- Trial name
- NCT07775391
- Testing
- hUC-MSCs Injection (Phase I), hUC-MSCs Injection (Phase IIa)
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Shenzhen Wingor Biotechnology Co., Ltd.
Primary Immune Thrombocytopenia (ITP)
An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
It is a clinical trial of a medicinal product Human Immunoglobulin for Intravenous Injection (5%) manufactured by Grand Shuyang Life Sciences (Chengdu) Co., Ltd. (hereinafter referred to as 5% IVIG).
- Trial name
- NCT07233213
- Testing
- Human immunoglobulin (pH4) for intravenous injection
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
Cancer, Hematologic Diseases
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia
The goal of this clinical research study is to find the dose of EZN-2232 that can be given to MBL deficient pediatric cancer patients undergoing chemotherapy.
- Conditions
- Cancer, Hematologic Diseases, Fever, Neutropenia
- Trial name
- NCT00520325
- Testing
- Intravenous recombinant human mannose binding lectin
- Sponsor
- Enzon Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.